Loading
A phase 2 trial of DZD8586 in chronic lymphocytic leukaemia, run by Dizal Pharmaceuticals, now recruiting.
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) is a phase 2 interventional study registered as NCT06539182 by Dizal Pharmaceuticals, with 155 participants planned, started 2024-04-29 and due to reach its primary completion in 2027-09. Interventions recorded: DZD8586.
Shares DZD8586, Dizal Pharmaceutical, Chronic lymphocytic leukaemia and the tag pipeline.
Shares DZD8586, Dizal Pharmaceutical, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Dizal Pharmaceutical and the tag pipeline.